ArticleNature communications2024
Long-term relapse-free survival enabled by integrating targeted antibacteria in antitumor treatment.
Article in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Machine Learning-Optimized Single-Atom Catalysts Enable Microenvironment-Adaptive Chemodynamic-Bioorthogonal Cancer Therapy.Advanced materials (Deerfield Beach, Fla.) · 2026Article
- Decoding and exploiting intratumoral microbiota: from microenvironment modulation to clinical intervention.Molecular biology reports · 2026Review
- Resiquimod-loaded MOF525 enables synergistic photodynamic therapy and immunotherapy for colorectal cancer.Nano convergence · 2026Article
- Lactylation-drived TRIM29 induces invasive behavior and lymph node metastasis in gastric cancer via hnRNPA1-mediated Wnt/β-catenin pathway.Cell death & disease · 2026Article
- Research on microbial communities in tumor microenvironments: cutting-edge dynamics and future trends from a bibliometric perspective.Frontiers in immunology · 2026Review
- Interplay between the gut microbiota, its metabolites and carcinogens.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025Review
- Golden insights for exploring cancer: delivery, from genes to the human body using bimetallic Au/Ag nanostructures.Discover oncology · 2025Review
- Tumor microenvironment as a complex milieu driving cancer progression: a mini review.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025Review
- Lactobacillus gasseri prevents ibrutinib-associated atrial fibrillation through butyrate.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2025Article
- The role of the gut microbiota in shaping the tumor microenvironment and immunotherapy of breast cancer.Frontiers in microbiology · 2025Review
- Microbial infection and treatment strategies in cancer patients.Frontiers in microbiology · 2025Review
- Metabolic reprogramming and therapeutic resistance in primary and metastatic breast cancer.Molecular cancer · 2024Review
- Interactions between the tumor microbiota and breast cancer.Frontiers in cellular and infection microbiology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
The role of tumor-resident intracellular microbiota (TRIM) in carcinogenesis has sparked enormous interest. Nevertheless, the impact of TRIM-targeted antibacteria on tumor inhibition and immune regulation in the tumor microenvironment (TME) remains unexplored. Herein, we report long-term relapse-free survival by coordinating antibacteria with antitumor treatment, addressing the aggravated immunosuppression and tumor overgrowth induced by TRIM using breast and prostate cancer models. Combining Ag
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.